GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

When Camryn Clements’ husband, an internal medicine doctor in training at the time, faced a series of health issues, the ...

The global fatty liver treatment market, valued at approximately USD 20 Billion in 2022, is anticipated to witness ...

We spoke to a a primary care physician for tips on how to prioritize our health as we age — from our 30s through our 70s and ...

The study highlights BMI's role in mediating genetic risk for diseases, suggesting a complex relationship with conditions ...

In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver ...

Unexplained fluctuations in cholesterol levels have been linked to dementia and cognitive decline in a recent study.

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than ...

A recent study by scientists at deCODE genetics, published in Nature Communications, offers new insights into how body mass ...

2 There are currently no treatments approved for MASLD, formerly known as nonalcoholic fatty liver disease. Instead, ...

Nonalcoholic fatty liver disease is the most common liver disease in America. If you have any of these fatty liver symptoms ...

Metabolic Dysfunction-Associated Steatohepatitis [MASH] is characterized as fatty liver disease, whereby there is a buildup ...